Clinical Trials Logo
  1. Home
  2. SLE
  3. NCT06182969

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

SLE Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Clinical Trial Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled Phase I/II study. About 40 participants will be recruited to receive either APG-2575 or a placebo, with doses from 200mg up to 800mg. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06182969
Study type Interventional
Source Ascentage Pharma Group Inc.
Contact Yifan Zhai
Phone 240-505-6608
Email Yzhai@ascentage.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date December 2023
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05479071 - Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
Completed NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response N/A
Active, not recruiting NCT05748925 - Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT04517240 - A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Terminated NCT01946880 - Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Phase 2
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT03240536 - Choosing Tests Wisely in Rheumatology N/A
Completed NCT04368299 - Telemedicine for Follow-up of Systemic Lupus Erythematosus N/A
Active, not recruiting NCT04037293 - Premature Atherosclerosis in Systemic Lupus Erythematosus
Not yet recruiting NCT04234633 - Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
Completed NCT01207297 - Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Phase 1
Terminated NCT00152555 - Physical Therapy for Systemic Lupus Erythematosus (SLE) N/A
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A
Completed NCT04806113 - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Phase 3
Recruiting NCT05966480 - Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Phase 2
Completed NCT03155477 - Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D N/A
Recruiting NCT05342285 - Flow Mediated Dilation in Association With Hyperuricemia
Not yet recruiting NCT03984227 - New Signaling Pathway Targeting Systemic Lupus Erythematosus
Enrolling by invitation NCT03144063 - Improving the Assessment of SLE Disease Activity N/A